Julie Cooke - 12 Feb 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Human Resources Officer
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
12 Feb 2026
Net transactions value
-$954,712
Form type
4
Filing time
17 Feb 2026, 17:46:18 UTC
Previous filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cooke Julie Chief Human Resources Officer 6027 EDGEWOOD BEND CT., SAN DIEGO /s/ Darin Lippoldt, Attorney-in-Fact 17 Feb 2026 0001776977

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $0 +1,387 +5% $0.000000 28,989 12 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $92,202 -749 -2.6% $123.10 28,240 12 Feb 2026 Direct F1
transaction NBIX Common Stock Options Exercise $0 +1,401 +5% $0.000000 29,641 13 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $93,835 -756 -2.6% $124.12 28,885 13 Feb 2026 Direct F1
transaction NBIX Common Stock Options Exercise $0 +1,510 +5.2% $0.000000 30,395 13 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $101,158 -815 -2.7% $124.12 29,580 13 Feb 2026 Direct F1
transaction NBIX Common Stock Award $0 +9,968 +34% $0.000000 39,548 13 Feb 2026 Direct F2
transaction NBIX Common Stock Tax liability $667,517 -5,378 -14% $124.12 34,170 13 Feb 2026 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Restricted Stock Unit Options Exercise $0 -1,387 -25% $0.000000 4,161 12 Feb 2026 Common Stock 1,387 Direct F4, F5
transaction NBIX Restricted Stock Unit Options Exercise $0 -1,401 -33% $0.000000 2,802 13 Feb 2026 Common Stock 1,401 Direct F4, F6
transaction NBIX Restricted Stock Unit Options Exercise $0 -1,510 -50% $0.000000 1,510 13 Feb 2026 Common Stock 1,510 Direct F4, F7
transaction NBIX Stock Option Award $0 +27,100 $0.000000 27,100 13 Feb 2026 Common Stock 27,100 $124.12 Direct F8
transaction NBIX Restricted Stock Unit Award $0 +4,754 $0.000000 4,754 13 Feb 2026 Common Stock 4,754 Direct F4, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.
F2 On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.
F3 32,306 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.
F4 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F5 This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,387 shares on February 12, 2026, and will vest as to 1,387 shares on February 12, 2027, 1,387 shares on February 12, 2028, and 1,387 shares on February 12, 2029, subject to the terms and conditions of the award.
F6 This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,401 shares on February 13, 2025, vested as to 1,401 shares on February 13, 2026, and will vest as to 1,401 shares on February 13, 2027, and 1,401 shares on February 13, 2028, subject to the terms and conditions of the award.
F7 This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,509 shares on February 13, 2024, vested as to 1,509 shares on February 13, 2025, vested as to 1,510 shares on February 13, 2026, and will vest as to 1,510 shares on February 13, 2027, subject to the terms and conditions of the award.
F8 Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F9 The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.